Deal to focus on development and commercialization in key emerging countries.
Abbott officially announced an agreement with mAbxience Holdings SL to commercialize several biosimilars focusing on oncology, women's health, and respiratory diseases in emerging markets. With the first molecules expected to launch in 2025, Abbott will register and commercialize the biosimilars, with mAbxience Holdings focusing on development, manufacturing, and supplying the necessary molecules. The partnership expands an existing agreement with mAbxience, initiated in Latin America in 2018.
"The expanded collaboration with mAbxience will complement our existing branded generic medicines portfolio with state-of-the-art biosimilars," said Daniel Salvadori,EVP, group president, established pharmaceuticals and nutritional products, Abbott. "With our large footprint in emerging countries and our commitment to put access and affordability at the center of what we do, this strategic collaboration will help more people in more places have access to affordable biosimilar medicines."
Reference: ABBOTT BROADENS ACCESS TO CUTTING-EDGE BIOSIMILARS IN KEY EMERGING MARKETS. Abbott. September 20, 2023. Accessed September 21, 2023. https://abbott.mediaroom.com/2023-09-20-Abbott-Broadens-Access-to-Cutting-Edge-Biosimilars-in-Key-Emerging-Markets
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased Engagement
March 28th 2024The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.